-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown epidemic continues to rage, and pharmaceutical companies are also stepping up their efforts to develop anti-epidemic weapons
As of April 13, a total of 986 drugs (including vaccines) have been developed for COVID-19 indications worldwide
In terms of drug types, there are 360 chemical drugs, 596 biological drugs, 19 traditional Chinese medicines and 11 other types of drugs
From the perspective of research and development progress, 39 new crown products have been approved for listing, and another 6 have applied for listing
From the perspective of layout companies, the company that has disclosed the most products related to COVID-19 indications is Roche (20), followed by AstraZeneca (19) and Pfizer (19).
The domestic companies/institutions that disclosed the most products related to COVID-19 indications are Shanghai Institute of Materia Medica (8), Fosun Pharma (7), Ascletis Pharma (6) and Emmy Vaccine (6), and CMS Companies such as Pharmaceuticals, China Cell, Wuhan Institute of Virology, Danxu Bio, Innovent Bio, and Watson Bio have all deployed more than 3 projects on COVID-19 indications
From the perspective of market returns, Pfizer is undoubtedly the biggest winner.
The world is an organic whole that is universally connected.
